文献速递耳科与耳神经

878例散发性前庭神经鞘瘤患者的听力状况与听觉康复特征

Hearing Status and Aural Rehabilitative Profile of 878 Patients With Sporadic Vestibular Schwannoma.
PubMed 文献 · Laryngoscope · 2020-12-09

该研究对878例散发性前庭神经鞘瘤患者进行横断面调查,发现62.2%未使用任何听力辅助设备。接受过肿瘤治疗的患者中41.9%曾使用过听力康复设备,高于观察组的27.0%(P < .001)。结论认为多数患者能适应单侧听力损失或对现有设备效果不满意。

要点

  • 62.2%的散发性前庭神经鞘瘤患者未使用任何听力辅助设备。
  • 肿瘤治疗组曾用听力康复设备比例41.9%,高于观察组的27.0%(P < .001)。
  • 同侧听力功能正常者中26.5%曾使用至少一种听力设备。

核心结论

  • 即使在对听力康复选项认知较高的队列中,有单侧前庭神经鞘瘤病史的患者最终长期使用听力辅助设备者仍很少。
  • 这提示多数患者能充分适应单侧听力损失,或对当前设备获得的益处不满意。

研究设计与样本

  • 横断面调查研究,于2017年2月至2019年1月对 acoustic neuroma association 成员中诊断为散发性前庭神经鞘瘤者进行调查。
  • 共纳入878例受访者,采用自我报告结果确定听觉康复特征。

主要发现

  • 62.2%(546/878)在调查时未使用任何听力辅助设备。
  • 37.8%(332/878)使用听力辅助设备者中,32.8%(109/332)使用耳背式助听器,23.8%(79/332)使用对侧信号路由(CROS)助听器,21.7%(72/332)使用骨传导设备。
  • 曾接受肿瘤治疗者中41.9%(278/663)在管理期间曾使用听力康复设备,观察组为27.0%(58/215)(P < .001)。
  • 同侧耳有功能听力者275例中,26.5%(73/275)曾使用至少一种听力设备;24.0%(66/275)使用传统助听器,0.7%(2/275)使用CROS助听器,0.4%(1/275)使用骨传导设备。
  • 同侧耳无功能听力者575例中,44.9%(258/575)曾使用至少一种听力设备;13.0%(75/575)使用CROS助听器,12.3%(71/575)使用骨传导设备。

临床怎么用

  • 临床咨询时应告知患者多数单侧前庭神经鞘瘤患者长期可能不使用听力辅助设备。
  • 对曾接受肿瘤治疗的患者,可更早讨论听力康复选项,因其既往设备使用率较高。
  • 对同侧耳仍有功能听力者,传统助听器是曾使用设备中最常见类型。
  • 对同侧耳无功能听力者,CROS助听器和骨传导设备是曾使用设备中较常见类型。

局限性

  • 证据等级为4级。
  • 采用横断面调查和自我报告结果,可能存在回忆偏倚。
  • 调查对象为 acoustic neuroma association 成员,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: To examine the hearing status and aural rehabilitative profile in a national cohort of patients with sporadic vestibular schwannoma (VS). STUDY DESIGN: Cross-sectional survey METHODS: A cross-sectional survey of Acoustic Neuroma Association members diagnosed with sporadic VS was performed from February 2017 through January 2019. Self-reported results were used to determine the aural rehabilitative profile of respondents. RESULTS: Among survey respondents, 62.2% (546/878) were not using any hearing-assistive device at time of survey. For the 37.8% (332/878) that were utilizing hearing-assistive devices, 32.8% (109/332) reported using a behind-the-ear hearing aid, 23.8% (79/332) used a contralateral routing of signal (CROS) hearing aid, and 21.7% (72/332) used a bone conduction device. Notably, 41.9% (278/663) of patients who previously underwent tumor treatment reported utilizing a hearing rehabilitation device at some point during VS management compared to 27.0% (58/215) of those undergoing observation with serial imaging (P < .001). Of 275 patients with functional hearing in the ipsilateral ear, 26.5% (73/275) reported having used at least one type of hearing device; 24.0% (66/275) reported use of a conventional hearing aid, 0.7% (2/275) a CROS aid, and 0.4% (1/275) a bone conduction device. Among respondents reporting ipsilateral nonfunctional hearing, 44.9% (258/575) reported having used at least one type of hearing device; 13.0% (75/575) a CROS aid, and 12.3% (71/575) a bone conduction device. CONCLUSIONS: Even among a cohort with presumably elevated literacy surrounding hearing rehabilitation options, few patients with a history of unilateral vestibular schwannoma ultimately use hearing assistive devices long-term, suggesting that most patients sufficiently adjust to unilateral hearing loss or are unsatisfied with the benefits achieved with current device options. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:1378-1381, 2021.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Macielak RJ, Marinelli JP, Spear SA, et al. Hearing Status and Aural Rehabilitative Profile of 878 Patients With Sporadic Vestibular Schwannoma. Laryngoscope. 2020. PMID: 33296080. doi:10.1002/lary.29315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。